Video

Unmet Needs, Future Directions, and Clinical Pearls in mCRPC

Author(s):

Stephen J. Freedland, MD

Dr. Freedland closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing some clinical pearls for community oncologists treating patients with the disease.

Current Time 0:00
Duration 6:03
Loaded: 0%
Stream Type LIVE
Remaining Time 6:03
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Related Videos
    Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
    Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
    Rebecca A. Campbell, MD, answers a question during a Zoom video interview
    Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
    1 expert in this video
    Comparing Trials Studying Treatment Intensification In mHSPC
    An Overview of the ARANOTE Trial
    An Overview of the ARANOTE Trial
    Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
    Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
    Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
    Stephen J. Freedland, MD, on the benefits of mCRPC treatments translating to the real world
    Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
    Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
    Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
    Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
    Study data point to gender disparities in oncology research citations
    Study data point to gender disparities in oncology research citations
    Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
    Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
    Related Content
    Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
    May 15th 2025

    Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

    Tracey L. Krupski, MD Jeunice Owens-Walton, MD
    "The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
    April 27th 2025

    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

    Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
    Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
    Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC
    May 6th 2025

    Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

    Hannah Clarke
    Initial study results may be available as soon as the first half of 2026.
    Dr. Murphy on increasing diversity in cancer clinical trials
    February 29th 2024

    Dr. Murphy on increasing diversity in cancer clinical trials

    Urology Times staff
    In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
    Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
    Published: April 29th 2025 | Updated: April 29th 2025

    Ultra-low PSA responses are more prevalent with darolutamide plus ADT

    Benjamin P. Saylor
    The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
    ARANOTE substudy highlights benefits of darolutamide in Black men
    April 28th 2025

    ARANOTE substudy highlights benefits of darolutamide in Black men

    Benjamin P. Saylor
    The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.
    © 2025 MJH Life Sciences

    All rights reserved.